AbCellera Biologics Inc. (ABCL)
NASDAQ: ABCL · Real-Time Price · USD
6.17
+0.40 (6.93%)
At close: Oct 8, 2025, 4:00 PM EDT
6.22
+0.05 (0.81%)
After-hours: Oct 8, 2025, 5:03 PM EDT
AbCellera Biologics Revenue
AbCellera Biologics had revenue of $17.08M in the quarter ending June 30, 2025, with 133.29% growth. This brings the company's revenue in the last twelve months to $32.88M, down -0.54% year-over-year. In the year 2024, AbCellera Biologics had annual revenue of $28.83M, down -24.17%.
Revenue (ttm)
$32.88M
Revenue Growth
-0.54%
P/S Ratio
52.06
Revenue / Employee
$55,161
Employees
596
Market Cap
1.84B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 28.83M | -9.19M | -24.17% |
Dec 31, 2023 | 38.03M | -447.40M | -92.17% |
Dec 31, 2022 | 485.42M | 110.22M | 29.38% |
Dec 31, 2021 | 375.20M | 142.05M | 60.92% |
Dec 31, 2020 | 233.16M | 221.54M | 1,907.88% |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 422.82B |
Johnson & Johnson | 90.63B |
Merck & Co. | 63.62B |
AbbVie | 58.33B |
AstraZeneca | 56.50B |
Novartis AG | 55.19B |
Eli Lilly and Company | 53.26B |
Novo Nordisk | 49.11B |
ABCL News
- 1 day ago - AbCellera to Participate at Upcoming Investor Conferences in November and December 2025 - Business Wire
- 2 days ago - AbCellera Biologics: Entering Growth Phase After A Pause - Seeking Alpha
- 9 days ago - AbCellera to Report Third Quarter 2025 Financial Results on November 6, 2025 - Business Wire
- 4 weeks ago - AbCellera Appoints Dr. Sarah Noonberg as Chief Medical Officer - Business Wire
- 6 weeks ago - AbCellera Doses First Participants in a Phase 1 Clinical Trial of ABCL575 - Business Wire
- 2 months ago - AbCellera to Participate at Upcoming Investor Conferences in September - Business Wire
- 2 months ago - AbCellera Biologics Inc. (ABCL) Q2 2025 Earnings Call Transcript - Seeking Alpha
- 2 months ago - AbCellera Reports Q2 2025 Business Results & First Participants Dosed in a Phase 1 Clinical Trial of ABCL635 for Vasomotor Symptoms - Business Wire